Selina M. Luger, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the importance of defining patient risk group when making decisions about consolidation therapy in acute myeloid leukemia (AML). Prof. Luger explains how cytarabine is used to approach remission therapy for the core binding factor AML risk group, whereas allogeneic bone marrow transplants are usually recommended as remission therapy for patients with poor prognostic factors. Prof. Luger further comments on approaches for intermediate risk groups, where measurable residual disease (MRD), karyotype and molecular analysis are required to determine a suitable consolidation therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.